小细胞肺癌伴融合对四线安罗替尼治疗部分缓解：一例报告
Small cell lung carcinoma with fusion partially responded to the 4-line therapy with anlotinib: A case report.
作者信息
Zhang Rui, He Yu-Ting, Liu Yi-Sha, Li Hang, Zhao Feng
机构信息
Meat Processing Key Laboratory of Sichuan Province, College of Food and Biological Engineering, Chengdu University, Chengdu 610106, Sichuan Province, China.
School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China.
出版信息
World J Clin Cases. 2024 Aug 16;12(23):5410-5415. doi: 10.12998/wjcc.v12.i23.5410.
BACKGROUND
Small cell lung cancer (SCLC) exhibits a pronounced tendency for metastasis and relapse, and the acquisition of resistance to chemotherapy and radiotherapy, leading to complexity in treatment outcomes. It is crucial to tackle these challenges by advancing targeted therapeutic approaches in ongoing research endeavors. Variant RET fusions have been reported in several solid tumors, but are rarely reported in SCLC.
CASE SUMMARY
We present the first case of a fusion in a 65-year-old male patient with SCLC. To date, the patient has received the 4th line chemotherapy with anlotinib for one year and has shown a sustained favorable partial response. According to the results of next generation sequencing, this SCLC patient harbors the fusion, suggesting that RET fusion could serve as a promising molecular target for SCLC treatment. Next-generation sequencing (NGS) plays a critical role in comprehensively assessing the genotype and phenotype of cancer.
CONCLUSION
NGS can provide SCLC patients with personalized and targeted therapy options, thereby improving their likelihood of survival.
背景
小细胞肺癌（SCLC）具有明显的转移和复发倾向，并且会对化疗和放疗产生耐药性，导致治疗结果复杂。在当前的研究工作中，通过推进靶向治疗方法来应对这些挑战至关重要。变异的RET融合在几种实体瘤中已有报道，但在SCLC中鲜有报道。
病例摘要
我们报告了首例65岁男性SCLC患者存在RET融合的病例。迄今为止，该患者接受安罗替尼第4线化疗已1年，显示出持续良好的部分缓解。根据二代测序结果，该SCLC患者存在RET融合，提示RET融合可能是SCLC治疗的一个有前景的分子靶点。二代测序（NGS）在全面评估癌症的基因型和表型方面发挥着关键作用。
结论
NGS可为SCLC患者提供个性化和靶向治疗方案，从而提高其生存几率。
Zotero 插件